ArticleJournal of clinical neurology (Seoul, Korea)2025
Real-World Experience of Lasmiditan for the Acute Treatment of Migraine.
Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan.Neurology and therapy · 2026Article
- Current landscape of migraine care with expert consensus from East Asia.The journal of headache and pain · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
background and purposeWe aimed to determine efficacy, safety, and predictors of response and side effects of lasmiditan in Korean patients with migraine.
methodsWe prospectively recruited patients who took lasmiditan at the Seoul National University Hospital between April 2023 and March 2024. We collected data on treatment, adverse events, and dosage adjustment profiles. Tolerability was defined as dosage maintenance or dosage increase. Logistic regression analyses were performed to identify predictors of a response to lasmiditan and adverse events.
resultsThis study included 154 patients. At visit 1, 110 (71.4%) and 44 (28.6%) patients were prescribed 50 and 100 mg of lasmiditan daily, respectively, with a treatment response observed at visit 2 in 49 (44.5%) and 20 (45.5%) patients, respectively. Adverse events were reported in 75 (48.7%) patients. Multivariate logistic analyses showed that female sex (odds ratio [OR]= 4.51, 95% confidence interval [CI]=1.43-14.19,
conclusionsThis was the first real-world study of lasmiditan in Korean patients with migraine. Although administered at a low dosage, lasmiditan was effective in approximately half of the patients. Dizziness was the most common adverse event, and it occurred at a higher rate than in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.